BMJ1d
AB0341 EFFICACY AND DRUG SURVIVAL AFTER MULTIPLE-SWITCHING FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILARS ABP501 AND SB5: A REAL-LIFE STUDY
1 Azienda Ospedaliero Universitaria Città Della Salute e della Scienza di Torino, Rheumatology Unit, Turin, Italy 2 Azienda Ospedaliero Universitaria di Parma, Department of Medicine, Internal ...
BMJ2d
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis
Objective Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can ...
BMJ2d
IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study
Objective To evaluate the efficacy and safety of the immunotherapeutic vaccine interferon-α kinoid (IFN-K) in a 36-week (W) phase IIb, randomised, double-blind, placebo (PBO)-controlled trial in ...
BMJ3d
OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
2 Evidera, Patient-Centered Research, Waltham, MA, United States of America 3 Evidera, Bethesda, MD, United States of America 4 Pfizer Inc, Inflammation and Immunology, Groton, CT, United States of ...
BMJ3d
CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice
The primary therapeutic target for rheumatoid arthritis is remission, assessed using validated composited measures.1 Currently, index-based remission frequently used in clinical practice are disease ...
BMJ6d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ7d
The EULAR–OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint
3 Department of Rheumatology, St George Hospital, University of NSW, Sydney, Australia 4 Department of Rheumatology, Diakonhjemmet Hospital, University of Oslo, Oslo, Norway 5 Academic Unit of ...
BMJ7d
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
Correspondence to Dr Jianguo Li, Rheumatology and Immunology, Capital Institute of Pediatrics, Beijing 100020, China; jianguo_li6{at}hotmail.com Among 25 cases, 44% (11/25) patients were female, the ...
BMJ7d
Genetics of rheumatoid arthritis: 2018 status
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
BMJ7d
Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system
1 Department of Rheumatology, University Medical Centre St Radboud, Nijmegen, The Netherlands 2 Department of Rheumatology, St Maartenshospital, Nijmegen, The Netherlands 3 Department of Medical ...
BMJ8d
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...